NDATOPICALCREAM
Approved
Nov 2013
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
4
Mechanism of Action
Cytochrome P450 2C19 Inhibitors
Pharmacologic Class:
Azole Antifungal
Clinical Trials (4)
Efficacy and Safety Study of Adjunctive Troriluzule in Obsessive Compulsive Disorder
Started Jan 2021
589 enrolled
Obsessive-Compulsive Disorder
Safety and Efficacy of Product 33525 (Luliconazole Cream 1%) in Pediatric Participants With Tinea Corporis
Started Feb 2016
75 enrolled
Tinea Corporis
Maximal Use of Luliconazole Cream 1% in Pediatric Participants With Moderate to Severe Tinea Pedis or Tinea Cruris
Started Dec 2015
30 enrolled
Tinea PedisTinea Cruris
Study Evaluating the Drug Interaction Potential of Luliconazole Cream 1% in Participants With Tinea Pedis and Tinea Cruris
Started Feb 2015
20 enrolled
Tinea PedisTinea Cruris
Loss of Exclusivity
LOE Date
Apr 28, 2034
99 months away
Patent Expiry
Apr 28, 2034